Nexentis Technologies Files Prospectus For Offering 2.573M Common Shares On Behalf Of Selling Shareholders

Nexentis Technologies Subsidiary MitoCareX Bio Narrows Its SLC Transport Protein Candidates To Select Candidate For A Drug Discovery Campaign

As previously disclosed, MitoCareX's broad structural analysis identified a set of SLC transport proteins outside its mitochondrial program that appeared compatible with the MITOLINE® enabled structural modelling.

Nexentis Technologies Subsidiary Completes Analysis Of SLC Transport Proteins, Starts Global AI Drug Discovery Initiative With Boltz

Nexentis Technologies Amends Its Loan And Partnership Agreement With Solterra Renewable Energy, Other Lenders For Melz Solar Project; Solterra To Make Early Partial Repayments Of ~$147K On Its Part Of Loan, $98K For Sale Of 10% Of Its Profit Rights;